Kyprolis-Plus-Darzalex Boosts Amgen's Myeloma Pipeline, After MCL-1 Drugs' Clinical Holds
The company's proteasome inhibitor reduced the risk of death in combination with J&J's CD38 inhibitor in a Phase III trial. A day earlier, Amgen reported clinical holds on its Phase I MCL-1 inhibitors due to cardiac safety.
You may also be interested in...
The Danish biotech will be getting more revenues from its J&J-partnered multiple myeloma blockbuster following a new US approval. Analysts are impressed with the way Genmab is spending the money.
Karyopharm's selinexor could be the next novel drug approved for multiple myeloma, which has seen a deluge of new treatment regimens. With room for improvement, the pipeline is full of milestones for approved and new therapies.
Some of the most anticipated data at ASH are for therapies targeting BCMA in multiple myeloma, including a next-gen CAR-T from bluebird and Celgene as well as Amgen's novel BiTE, but an update from China's Legend Biotech and J&J could steal the show.